sirolimus oncology
Selected indexed studies
- Everolimus for advanced pancreatic neuroendocrine tumors. (N Engl J Med, 2011) [PMID:21306238]
- Everolimus. (Recent Results Cancer Res, 2014) [PMID:24756805]
- A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. (Cancer Med, 2024) [PMID:39487711]
_Worker-drafted node — pending editorial review._
Connections
sirolimus oncology is a side effect of
Sources
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. (2018) pubmed
- Everolimus. (2014) pubmed
- Everolimus for advanced pancreatic neuroendocrine tumors. (2011) pubmed
- A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. (2024) pubmed
- mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma. (2024) pubmed
- Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: A randomized clinical trial. (2025) pubmed
- Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. (2024) pubmed
- Transplantation and tumors. (2006) pubmed
- Temsirolimus-induced glomerulopathy. (2009) pubmed
- Sirolimus use and cancer incidence among US kidney transplant recipients. (2015) pubmed